TP53 and neoplasm: NGS did not identify actionable driver mutations but did detect alterations in AKT1, MAP2K1, and TP53, along with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score [TPS]: 50%; Figure 2E).